CM
CDTX

Crestline Management’s Cidara Therapeutics CDTX Stock Holding History

Crestline Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,952
Closed -$156K – 246
2018
Q1 		$156K Buy
+1,952
New +$267K 0.02% 209

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Crestline Management's CDTX Position: Q2 2018 in Review

Crestline Management sold out of Cidara Therapeutics (CDTX) in Q2 2018, closing a stake of 1,952 shares — an estimated $156K sold.

Crestline Management first reported a position in CDTX in Q1 2018 and held it in 1 quarter. The position peaked at $156K in Q1 2018. 56 funds tracked by Wall St. Rank hold CDTX as of Q2 2018.

  • Crestline Management reported no remaining Cidara Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Crestline Management sold 1,952 Cidara Therapeutics shares in Q2 2018, an estimated $156K.
  • Crestline Management first reported a position in Cidara Therapeutics in Q1 2018 and held it in 1 quarter.
  • Crestline Management's Cidara Therapeutics position peaked at $156K in Q1 2018.
  • 56 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2018.

Based on Crestline Management's 13F filing for Q2 2018, filed 14 Aug 2018.